Jan 08, 2024 / 07:15PM GMT
Jessica Macomber Fye - JPMorgan Chase & Co, Research Division - Analyst
Good morning, everyone. My name is Jess Fye. I'm a Senior Biotech Analyst at JPMorgan, and we're delighted to be continuing the conference today with United Therapeutics. I'm joined by the company's CEO, Dr. Martine Rothblatt, He's going to give you a presentation on the company, and then we're going to move right into Q&A.
(Operator Instructions)
So with that, let me turn it over to Martine.
Martine A. Rothblatt - United Therapeutics Corporation - Founder, Chairman & CEO
Thank you, Jess, and good morning, everyone. I'm here to give our company presentation on United Therapeutics, our tagline Enabling Inspiration. Here's our standard safe harbor statement, and please review it. United Therapeutics has a key focus on rare diseases, specifically pulmonary hypertension, pulmonary fibrosis and neuroblastoma.
In addition, we have a second focus in the field of organ manufacturing. And there, we are working on 4 key types of technologies: ex-vivo lung
United Therapeutics Corp at JPMorgan Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot